Challenges in systematic reviews that evaluate drug efficacy or effectiveness

被引:21
作者
Santaguida, PL
Helfand, M
Raina, P
机构
[1] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada
[2] Portland VA Med Ctr, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Evidence Based Pract Ctr, Portland, OR USA
关键词
D O I
10.7326/0003-4819-142-12_Part_2-200506211-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increasingly, consumers, clinicians, regulatory bodies, and insurers are using systematic reviews of drug interventions to select treatments and set policies. Although a systematic review cannot provide all the information a clinician needs to make an informed choice for therapy, it can help decision makers distinguish what claims about effectiveness are based on evidence, identify critical information gaps, describe features of the evidence that limit applicability in practice, and address whether drug effectiveness differs for particular subgroups of patients. To improve the relevance and validity of reviews of drug therapies, reviewers need to delineate clinically important subgroups, specific aims of therapy, and most important outcomes. They may need to find unpublished trials, studies other than direct comparator (head-to-head) trials, and additional details of published trials from pharmaceutical manufacturers and regulatory agencies. In this paper, we address ways to formulate questions relevant to specific clinical therapeutic aims; discuss types of studies to include in drug efficacy and effectiveness reviews and how to find them; and describe ways to assess applicability of studies to actual practice.
引用
收藏
页码:1066 / 1072
页数:7
相关论文
共 38 条
[21]   Network meta-analysis for indirect treatment comparisons [J].
Lumley, T .
STATISTICS IN MEDICINE, 2002, 21 (16) :2313-2324
[22]   Design and analysis of two-period studies of potentially disease-modifying treatments [J].
McDermott, MP ;
Hall, WJ ;
Oakes, D ;
Eberly, S .
CONTROLLED CLINICAL TRIALS, 2002, 23 (06) :635-649
[23]  
MULROW CD, 1999, AHCPR PUBLICATION
[24]   Publication bias in situ [J].
Phillips C.V. .
BMC Medical Research Methodology, 4 (1)
[25]   Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension [J].
Psaty, BM ;
Smith, NL ;
Heekbert, SR ;
Vos, HL ;
Lemaitre, RN ;
Reiner, AP ;
Siscovick, DS ;
Bis, J ;
Lumley, T ;
Longstreth, WT ;
Rosendaal, FR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1680-1689
[26]   Health outcomes associated with various antihypertensive therapies used as first-line agents - A network meta-analysis [J].
Psaty, BN ;
Lumley, T ;
Furberg, CD ;
Schellenbaum, G ;
Pahor, M ;
Alderman, MH ;
Weiss, NS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (19) :2534-2544
[27]   Treating Individuals 1 - External validity of randomised controlled trials: "To whom do the results of this trial apply?"' [J].
Rothwell, PM .
LANCET, 2005, 365 (9453) :82-93
[28]  
SANTAGUIDA PS, 2004, AHRQ PUBLICATION
[29]  
Shekelle P, 2003, AHRQ PUBLICATION, V03-E023
[30]   Pharmacologic management of acute attacks of migraine and prevention of migraine headache [J].
Snow, V ;
Weiss, K ;
Wall, EM ;
Mottur-Pilson, C .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (10) :840-849